Evidence map›Paper›PMID 39870771›Full record

ArticleScientific reports2025

Cross-sectional study of proteomic differences between moderate and severe psoriasis.

Lingling Wu, Chen Cen, Bibo Xie, Lihua Hu, Jia Huang, Ningning Shen, Qiang Dong

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lingling Wu *Department of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Chen Cen *Department of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Bibo XieDepartment of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Lihua HuDepartment of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Jia HuangDepartment of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Ningning ShenDepartment of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Qiang DongDepartment of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China. QiangDong.edu@outlook.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although an ongoing understanding of psoriasis vulgaris (PV) pathogenesis, little is known about the proteomic differences between moderate and severe psoriasis. In this cross-sectional study, we evaluated the proteomic differences between moderate and severe psoriasis using data-independent acquisition mass spectrometry (DIA-MS). 173 differentially expressed proteins (DEPs) were significantly differentially expressed between the two groups. Among them, 85 proteins were upregulated, while 88 were downregulated (FC ≥ ± 1.5, P < 0.05). Eighteen DEPs were mainly enriched in the IL - 17 signalling pathway, Neutrophil extracellular trap formation, Neutrophil degranulation and NF - kappa B signalling pathway, which were associated with psoriasis pathogenesis. Ingenuity pathway Analysis (IPA) identified TNF and TDP53 as the top upstream up-regulators, while Lipopolysaccharide and YAP1 were the top potential down-regulators. The main active pathways were antimicrobial peptides and PTEN signalling, while the inhibitory pathways were the neutrophil extracellular trap pathway, neutrophil degranulation, and IL-8 signalling. 4D-parallel reaction monitoring (4D-PRM) suggested that KRT6A were downregulated in severe psoriasis. Our data identify Eighteen DEPs as biomarkers of disease severity, and are associated with IL - 17 signalling pathway, Neutrophil extracellular trap formation, NF - kappa B signalling pathway, and defence response to the bacterium. Targeting these molecules and measures to manage infection may improve psoriasis's severity and therapeutic efficacy.

Indexed as

ProteomeProteomicsPsoriasisAdultBiomarkersCross-Sectional StudiesFemaleHumansMaleMiddle AgedSeverity of Illness IndexSignal TransductionBiomarkersProteome4D-parallel reaction monitoringBiomarkerData-independent acquisition mass spectrometryIngenuity pathway analysisProteomicsPsoriasis vulgaris

Identifiers

PMID39870771
PMCPMC11772871

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.